KDR and neoplasm: Apatinib is a novel small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI) that blocks downstream signal transduction by highly selective competition for ATP-binding sites, resulting in strongly inhibited angiogenesis in tumor tissue (13).